Corrigendum to “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study” [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729](S0145212616301989)(10.1016/j.leukres.2016.09.012)

The authors regret to inform, that a key author (Dr. Brian A. Jonas MD PhD), was inadvertently omitted form the authorship of this manuscript at the time of publication. Dr. Jonas was a key contributor to the design, conception and data analysis of this work. He assisted in the writing and critical review of the manuscript. He satisfies ICMJE criteria for authorship. He enrolled a significant number of patients to this clinical trial and was an important member of the research team. On behalf of my colleagues, I would like to re-designate the authorship of this manuscript as follows (changes in bold): Ronan T. Swords MD, PhD, FRCPI, FRCPath ^a , Peter L. Greenberg, MD ^b , Andrew H. Wei, MBBS, PhD ^c , Simon Durrant, MBBS, MRCS, LRCP, FRCP, FRCPath ^d , Anjali S. Advani, MD ^e , Mark S Hertzberg, MBBS, PhD, FRACP, FRCPA ^f , Brian A. Jonas MD, PhD ^g , Ian D Lewis, MBBS, PhD ^h , Gabriel Rivera, MD ^b , Dita Gratzinger, MD, PhD ^b , Alice C. Fan, MD ^b , Dean W. Felsher, MD, PhD ^b , Jorge E. Cortes, MD ⁱ , Justin M. Watts, MD ^a , Geoff T. Yarranton, PhD ^j , Jackie M. Walling, MB, ChB, PhD ^j , and Jeffrey E. Lancet, MD ^k Authorship affiliations are as follows (changes in bold): ^a Leukemia Program, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, FL, United States (corresponding author). ^b Stanford Cancer Institute, Stanford, CA, United States ^c The Alfred Hospital and Monash University, Melbourne, Australia ^d The Royal Brisbane and Women's Hospital, Brisbane, Australia ^e Cleveland Clinic, Cleveland, OH, United States ^f Westmead Hospital, Westmead, Australia ^g Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, UC Davis Comprehensive Cancer Center, United States ^h The Royal Adelaide Hospital, Adelaide, Australia ⁱ The University of Texas MD Anderson Cancer Center, Houston, TX, United States ^j KaloBios Pharmaceuticals, Inc., South San Francisco, CA, United States ^k H Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States Please issue this corrigendum in the next issue of the journal. The authors would like to sincerely apologise for any inconvenience caused.